AC
AVDL

Armistice Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Armistice Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,836,000
Closed -$13.4M – 76
2018
Q1 		$13.4M Buy
1,836,000
+148,000
+9% +$1.3M 1.02% 36
2017
Q4 		$13.8M Hold
1,688,000
– – 1.38% 28
2017
Q3 		$17.7M Buy
1,688,000
+538,000
+47% +$5.14M 2.09% 11
2017
Q2 		$12.7M Buy
1,150,000
+194,000
+20% +$1.95M 1.62% 21
2017
Q1 		$9.25M Buy
956,000
+128,000
+15% +$1.28M 1.91% 22
2016
Q4 		$8.6M Buy
828,000
+228,000
+38% +$2.51M 2.04% 21
2016
Q3 		$7.44M Buy
600,000
+251,997
+72% +$3.29M 2.39% 15
2016
Q2 		$3.74M Buy
+348,003
New +$3.71M 1.42% 32

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armistice Capital's AVDL Position: Q2 2018 in Review

Armistice Capital sold out of Avadel Pharmaceuticals (AVDL) in Q2 2018, closing a stake of 1,836,000 shares — an estimated $13.4M sold.

Armistice Capital first reported a position in AVDL in Q2 2016 and held it in 8 quarters. The position peaked at $17.7M in Q3 2017. 75 funds tracked by Wall St. Rank hold AVDL as of Q2 2018.

  • Armistice Capital reported no remaining Avadel Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Armistice Capital sold 1,836,000 Avadel Pharmaceuticals shares in Q2 2018, an estimated $13.4M.
  • Armistice Capital first reported a position in Avadel Pharmaceuticals in Q2 2016 and held it in 8 quarters.
  • Armistice Capital's Avadel Pharmaceuticals position peaked at $17.7M in Q3 2017.
  • 75 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2018.

Based on Armistice Capital's 13F filing for Q2 2018, filed 14 Aug 2018.